Novel therapies and new targets of treatment for familial hypercholesterolemia

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 350-356

  Goldberg, Anne Carol ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Antisense oligonucleotide; Apolipoprotein B; Familial hypercholesterolemia; LDL cholesterol; MTP inhibitor; Thyroid hormone analogue

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; APOLIPOPROTEIN B; KEXIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; MIPOMERSEN; PROPROTEIN CONVERTASE 1; SQUALENE SYNTHASE INHIBITOR; SUBTILISIN; THYROID HORMONE; THYROID HORMONE DERIVATIVE; TRIACYLGLYCEROL;

BONE ATROPHY; CHOLESTEROL SYNTHESIS; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; FAMILIAL HYPERCHOLESTEROLEMIA; FOLLOW UP; HEART ARRHYTHMIA; HUMAN; MUSCLE ATROPHY; PHARMACODYNAMICS; PRIORITY JOURNAL; TACHYCARDIA;

APOLIPOPROTEINS B; CARRIER PROTEINS; CHOLESTEROL, LDL; FARNESYL-DIPHOSPHATE FARNESYLTRANSFERASE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; OLIGONUCLEOTIDES, ANTISENSE; SERINE ENDOPEPTIDASES; THYROID HORMONES;

EID: 77957867597     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.015     Document Type: Conference Paper

References (19)

1. E.A. Stein Other therapies for reducing low-density lipoprotein cholesterol: medications in development Endocrinol Metab Clin North Am 38 2009 99 119
2. M.H. Davidson Novel nonstatin strategies to lower low-density lipoprotein cholesterol Curr Atheroscler Rep 11 2009 67 70
3. F. Akdim, E.S. Stroes, and J.J. Kastelein Antisense apolipoprotein B therapy: where do we stand? Curr Opin Lipidol 18 2007 397 400
4. R.Z. Yu, R.S. Geary, and J.D. Flaim Lack of pharmacokinetic interaction of mipomersen sodium (ISIS 301012), a 2'-O-methoxyethyl modified antisense oligonucleotide targeting apolipoprotein B-100 messenger RNA, with simvastatin and ezetimibe Clin Pharmacokinet 48 2009 39 50
5. T. Thomas, and H. Ginsberg Development of apolipoprotein B antisense molecules as a therapy for hyperlipidemia Curr Atheroscler Rep 12 2010 58 65
6. J.J. Kastelein, M.K. Wedel, and B.F. Baker Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B Circulation 114 2006 1729 1735
7. F. Akdim, E.S. Stroes, and E.J. Sijbrands Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy J Am Coll Cardiol 55 2010 1611 1618
8. F. Akdim, M.E. Visser, and D.L. Tribble Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia Am J Cardiol 105 2010 1413 1419
9. F.J. Raal, R.D. Santos, and D.J. Blom Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial Lancet 375 2010 998 1006
10. ISIS Pharmaceuticals. Press release. Available at: http://ir.isispharm. com/phoenix.zhtml?c=222170&p=irol-newsArticle&ID=1385999&highlight. Accessed July 25, 2010.
11. M.E. Visser, F. Akdim, and D.L. Tribble Effect of apolipoprotein-B synthesis inhibition on liver triglyceride content in patients with familial hypercholesterolemia J Lipid Res 51 2010 1057 1062
12. K.R. Feingold Does inhibition of apolipoprotein B synthesis produce foie gras? J Lipid Res 51 2010 877 878
13. R.D. Neely, and M.F. Bassendine Antisense technology to lower LDL cholesterol Lancet 375 2010 959 961
14. T.R. Joy, and R.A. Hegele Microsomal triglyceride transfer protein inhibition - friend or foe? Nat Clin Pract Cardiovasc Med 5 2008 506 508
15. M. Cuchel, L.T. Bloedon, and P.O. Szapary Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia N Engl J Med 356 2007 148 156
16. F.F. Samaha, J. McKenney, L.T. Bloedon, W.J. Sasiela, and D.J. Rader Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia Nat Clin Pract Cardiovasc Med 5 2008 497 505
17. J.C. Cohen, E. Boerwinkle, T.H. Mosley Jr., and H.H. Hobbs Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 2006 1264 1272
18. J.D. Baxter, and P. Webb Thyroid hormone mimetics: potential applications in atherosclerosis, obesity and type 2 diabetes Nat Rev Drug Discov 8 2009 308 320
19. P.W. Ladenson, J.D. Kristensen, and E.C. Ridgway Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia N Engl J Med 362 2010 906 916